International Journal of Scientific Research in Dental and Medical Sciences

International Journal of Scientific Research in Dental and Medical Sciences

Intradermal Inoculation of Formalin Treated Escherichia Coli Produced Protective Antibody against Protein of Specific Molecular Weight in Mice Model

Document Type : Original Article

Authors
Farhana Parveen 1
SM Shamsuzzaman 1
Sonia Parveen 2
Kohinur Hasan 1
1 Department of Microbiology, Dhaka Medical College, Dhaka, Bangladesh
2 Department of Endocrinology, Combined Military Hospital, Dhaka, Bangladesh
10.30485/ijsrdms.2025.513630.1653
Abstract
Background and aim: Escherichia coli can cause serious infections in humans and animals while constituting a significant portion of the microbiota in many hosts. Due to the increasing global prevalence of multidrug-resistant (MDR) E. coli bacteria, it is vital to explore alternate therapeutic approaches, such as vaccines. This study was designed to detect a specific protein based on molecular weight in serum and splenic cell culture supernatant using a formalin-inactivated whole-cell vaccine against multidrug-resistant (MDR) E. coli.
Material and methods: This study used MDR E. coli obtained from clinical samples to immunize 15 Swiss albino mice intradermally. Fourteen days after the third immunization dose, mice were injected with live E. coli intraperitoneally and monitored for 14 days. Sera and spleen cell culture supernatants were obtained. E. coli antigens used in vaccine production were sonicated, and their molecular weights were determined by SDS-PAGE. ELISA was used to measure protective antibodies against antigens of different molecular weights.
Results: 100% of immunized mice survived after the lethal dose of live E. coli. The experimental group mice's pre- and post-challenge serum and splenic cell culture immunoglobulin G antibodies had noticeably greater optical density (OD) values than the control mice. E. coli proteins ranging from 11 to 17 kDa showed higher OD values in sera and splenic cell culture supernatant.
Conclusions: This indicates that E. coli antigens ranging from 11 to 17 kDa are more immunogenic and can be used as a potential vaccine formulation.
Keywords
Antibodies
Escherichia Coli
Immunization

Subjects

[1] Sora VM, Meroni G, Martino PA, Soggiu A, Bonizzi L, Zecconi A. Extraintestinal pathogenic Escherichia coli: Virulence factors and antibiotic resistance. Pathogens. 2021;10(11):1355. https://doi.org/10.3390/pathogens10111355.
[2] Poolman JT, Wacker M. Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. The Journal of infectious diseases. 2016;213(1):6-13. https://doi.org/10.1093/infdis/jiv429.
[3] Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infectious Disease Clinics. 2014;28(1):1-3. https://doi.org/10.1016/j.idc.2013.09.003.
[4] Pormohammad A, Nasiri MJ, Azimi T. Prevalence of antibiotic resistance in Escherichia coli strains simultaneously isolated from humans, animals, food, and the environment: a systematic review and meta-analysis. Infection and drug resistance. 2019:1181-97. http://doi.org/10.2147/IDR.S201324.
[5] Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen JA, Klugman K, et al. Access to effective antimicrobials: a worldwide challenge. The Lancet. 2016;387(10014):168-75. https://doi.org/10.1016/S0140-6736(15)00474-2.
[6] Qiu L, Chirman D, Clark JR, Xing Y, Hernandez Santos H, Vaughan EE, et al. Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): Progress and challenges. Gut Microbes. 2024;16(1):2359691. https://doi.org/10.1080/19490976.2024.2359691.
[7] Pace JL, Rossi HA, Esposito VM, Frey SM, Tucker KD, Walker RI. Inactivated whole-cell bacterial vaccines: current status and novel strategies. Vaccine. 1998;16(16):1563-74. https://doi.org/10.1016/S0264-410X(98)00046-2.
[8] Arshadi N, Mousavi SL, Amani J, Nazarian S. Immunogenic potency of formalin and heat inactivated E. coli O157: H7 in mouse model administered by different routes. Avicenna journal of medical biotechnology. 2020;12(3):194-200.
[9] Pulit-Penaloza JA, Esser ES, Vassilieva EV, Lee JW, Taherbhai MT, Pollack BP, et al. A protective role of murine langerin+ cells in immune responses to cutaneous vaccination with microneedle patches. Scientific reports. 2014;4(1):6094. https://doi.org/10.1038/srep06094.
[10] West R, Kobokovich A, Connell N, Gronvall GK. COVID-19 antibody tests: a valuable public health tool with limited relevance to individuals. Trends in microbiology. 2021;29(3):214-23. https://doi.org/10.1016/j.tim.2020.11.002.
[11] Roy S, Kumar V. A practical approach on SDS PAGE for separation of protein. International Journal of Science and Research. 2014;3(8):955- 
       60.
[12] Takahashi K, Hanamura Y, Tokunoh N, Kassai K, Matsunishi M, Watanabe S, et al. Protective effects of oral immunization with formalin-inactivated whole-cell Citrobacter rodentium on Citrobacter rodentium infection in mice. Journal of Microbiological Methods. 2019;159:62-8. https://doi.org/10.1016/j.mimet.2019.02.016.
[13] Kawser Z, Shamsuzzaman SM. Intradermal immunization with heat-killed Klebsiella pneumoniae leading to the production of protective immunoglobulin G in BALB/c mice. International Journal of Applied and Basic Medical Research. 2021;11(3):160-5. https://doi.org/10.4103/ijabmr.IJABMR_63_20.
[14] Agallou M, Karagouni E. Detection of antigen-specific T cells in spleens of vaccinated mice applying 3 [H]-thymidine incorporation assay and luminex multiple cytokine analysis technology. Bio-protocol. 2019;9(11):e3252. https://doi.org/10.21769/BioProtoc.3252.
[15] Green MR, Sambrook J. Molecular cloning. A Laboratory Manual 4th. 2012;448.
[16] Fischer R, Kessler BM. Gel-aided sample preparation (GASP)—A simplified method for gel‐assisted proteomic sample generation from protein extracts and intact cells. Proteomics. 2015;15(7):1224-9. https://doi.org/10.1002/pmic.201400436.
[17] Ramírez-Castillo FY, Moreno-Flores AC, Avelar-González FJ, Márquez-Díaz F, Harel J, Guerrero-Barrera AL. An evaluation of multidrug-resistant Escherichia coli isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study. Annals of clinical microbiology and antimicrobials. 2018;17:1-3. https://doi.org/10.1186/s12941-018-0286-5.
[18] Gohar A, Abdeltawab NF, Fahmy A, Amin MA. Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model. BMC research notes. 2016;9:1-8. https://doi.org/10.1186/s13104-016-1891-z.
[19] Rahjerdi AK, Jafari M, Salmanian AH. Immunogenic evaluation of bivalent vaccine Candidate against Enterohemorrhagic and Enterotoxigenic Escherichia coli. Iranian Journal of Immunology. 2019;16(3):200-11. https://doi.org/10.22034/iji.2019.80271.
[20] Zorgi NE, Galisteo AJ, Sato MN, Do Nascimento N, de Andrade HF. Immunity in the spleen and blood of mice immunized with irradiated Toxoplasma gondii tachyzoites. Medical microbiology and immunology. 2016;205:297-314. https://doi.org/10.1007/s00430-015-0447-5.
[21] Gu H, Liao Y, Zhang J, Wang Y, Liu Z, Cheng P, et al. Rational design and evaluation of an artificial Escherichia coli K1 protein vaccine candidate based on the structure of OmpA. Frontiers in cellular and infection microbiology. 2018;8:172. https://doi.org/10.3389/fcimb.2018.00172.
International Journal of Scientific Research in Dental and Medical Sciences
Volume 7, Issue 2
Spring 2025
Pages 48-52

  • Receive Date 08 March 2025
  • Revise Date 10 May 2025
  • Accept Date 16 May 2025
  • Publish Date 21 May 2025